Niowave is expanding its existing supply agreement with AstraZeneca to a 10-year commitment to deliver actinium-225 (Ac-225).
This follows AstraZeneca's decision to exercise its option to increase capacity. The agreement secures the supply of Ac-225 to advance AstraZeneca's growing portfolio of radioconjugates, a type of cancer treatment that uses radioactive particles to target and destroy cancer cells.
Niowave's proprietary superconducting linear accelerator technology and radiochemistry aim to address the challenge of destroying cancerous tumors while limiting harm to surrounding healthy tissues.
